Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.
Vaccine
; 25(50): 8460-8, 2007 Dec 05.
Article
em En
| MEDLINE
| ID: mdl-18022737
ABSTRACT
Previous studies with gonadotrophin releasing hormone (GnRH/LHRH) vaccines have shown the usefulness of immunization against this hormone in prostate cancer. To this end, we have generated a completely synthetic peptide modified at position 6 and attached to the 830-844 tetanic toxoid (TT) helper T cell sequence. Through this work we have demonstrated that the GnRHm1-TT molecule was highly immunogenic when it is formulated as an oil-based emulsion adjuvated with Montanide ISA 51. That results correlated directly with testosterone reduction and tumor growth inhibition of the Dunning R3327-H androgen responsive prostate tumor model in rats. GnRHm1-TT, proved to be safe and useful for future clinical trials.
Buscar no Google
Coleções:
01-internacional
Contexto em Saúde:
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Toxoide Tetânico
/
Hormônio Liberador de Gonadotropina
/
Vacinas Anticâncer
/
Imunoterapia
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Vaccine
Ano de publicação:
2007
Tipo de documento:
Article